Kelsey Monson, PhD
@kelseymonson.bsky.social
NCI K00 Postdoctoral Research Fellow @IcahnMountSinai | PhD @NYUGrossman | MS @ColumbiaMSPH | Defining molecular signatures of immunotherapy outcomes
7/
If you're interested in immunotherapy, metabolism, or precision oncology, give it a read:
🧬 www.nature.com/articles/s41...
If you're interested in immunotherapy, metabolism, or precision oncology, give it a read:
🧬 www.nature.com/articles/s41...
Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma - Nature Medicine
In this genomic analysis of peripheral blood samples of the phase 3 CheckMate-067 trial of ipilimumab (IPI) versus nivolumab (NIVO) versus ipilimumab and nivolumab (IPI-NIVO) in melanoma, the status o...
www.nature.com
June 5, 2025 at 3:50 PM
7/
If you're interested in immunotherapy, metabolism, or precision oncology, give it a read:
🧬 www.nature.com/articles/s41...
If you're interested in immunotherapy, metabolism, or precision oncology, give it a read:
🧬 www.nature.com/articles/s41...
6/
We hope this opens the door to more personalized immunotherapy strategies—where your mitochondrial DNA helps guide treatment decisions.
Big thanks to our incredible collaborators and patients who made this possible! 🙏
We hope this opens the door to more personalized immunotherapy strategies—where your mitochondrial DNA helps guide treatment decisions.
Big thanks to our incredible collaborators and patients who made this possible! 🙏
June 5, 2025 at 3:50 PM
6/
We hope this opens the door to more personalized immunotherapy strategies—where your mitochondrial DNA helps guide treatment decisions.
Big thanks to our incredible collaborators and patients who made this possible! 🙏
We hope this opens the door to more personalized immunotherapy strategies—where your mitochondrial DNA helps guide treatment decisions.
Big thanks to our incredible collaborators and patients who made this possible! 🙏
5/
This suggests that germline mitochondrial variation shapes how the immune system responds to cancer therapy.
It’s a new kind of biomarker—one that’s inherited and detectable from blood, not tumor tissue.
This suggests that germline mitochondrial variation shapes how the immune system responds to cancer therapy.
It’s a new kind of biomarker—one that’s inherited and detectable from blood, not tumor tissue.
June 5, 2025 at 3:50 PM
5/
This suggests that germline mitochondrial variation shapes how the immune system responds to cancer therapy.
It’s a new kind of biomarker—one that’s inherited and detectable from blood, not tumor tissue.
This suggests that germline mitochondrial variation shapes how the immune system responds to cancer therapy.
It’s a new kind of biomarker—one that’s inherited and detectable from blood, not tumor tissue.
4/
What might explain this?
We dug deeper using single-cell RNA-seq and found that HG-T patients had more naïve pre-treatment CD8+ T cells that were less responsive to nivolumab.
So the resistance may stem from baseline differences in immune cells—not just tumor features.
What might explain this?
We dug deeper using single-cell RNA-seq and found that HG-T patients had more naïve pre-treatment CD8+ T cells that were less responsive to nivolumab.
So the resistance may stem from baseline differences in immune cells—not just tumor features.
June 5, 2025 at 3:50 PM
4/
What might explain this?
We dug deeper using single-cell RNA-seq and found that HG-T patients had more naïve pre-treatment CD8+ T cells that were less responsive to nivolumab.
So the resistance may stem from baseline differences in immune cells—not just tumor features.
What might explain this?
We dug deeper using single-cell RNA-seq and found that HG-T patients had more naïve pre-treatment CD8+ T cells that were less responsive to nivolumab.
So the resistance may stem from baseline differences in immune cells—not just tumor features.
3/
Even after accounting for known biomarkers like tumor mutational burden (TMB) and PD-L1 expression, HG-T still predicted resistance—especially to anti-PD-1 therapy (nivolumab), whether used alone or in combination.
This was consistent across both datasets.
Even after accounting for known biomarkers like tumor mutational burden (TMB) and PD-L1 expression, HG-T still predicted resistance—especially to anti-PD-1 therapy (nivolumab), whether used alone or in combination.
This was consistent across both datasets.
June 5, 2025 at 3:50 PM
3/
Even after accounting for known biomarkers like tumor mutational burden (TMB) and PD-L1 expression, HG-T still predicted resistance—especially to anti-PD-1 therapy (nivolumab), whether used alone or in combination.
This was consistent across both datasets.
Even after accounting for known biomarkers like tumor mutational burden (TMB) and PD-L1 expression, HG-T still predicted resistance—especially to anti-PD-1 therapy (nivolumab), whether used alone or in combination.
This was consistent across both datasets.
2/
We looked at over 1,200 patients with metastatic melanoma treated with ICIs, across two cohorts: CheckMate-067 (a clinical trial) and IO-GEM (standard-of-care).
We found that people with mitochondrial haplogroup T (HG-T) were much less likely to benefit from therapy.
We looked at over 1,200 patients with metastatic melanoma treated with ICIs, across two cohorts: CheckMate-067 (a clinical trial) and IO-GEM (standard-of-care).
We found that people with mitochondrial haplogroup T (HG-T) were much less likely to benefit from therapy.
June 5, 2025 at 3:50 PM
2/
We looked at over 1,200 patients with metastatic melanoma treated with ICIs, across two cohorts: CheckMate-067 (a clinical trial) and IO-GEM (standard-of-care).
We found that people with mitochondrial haplogroup T (HG-T) were much less likely to benefit from therapy.
We looked at over 1,200 patients with metastatic melanoma treated with ICIs, across two cohorts: CheckMate-067 (a clinical trial) and IO-GEM (standard-of-care).
We found that people with mitochondrial haplogroup T (HG-T) were much less likely to benefit from therapy.
One of the best things about being a researcher in NYC is that there is always great science happening right in your backyard 🧬🗽
March 27, 2025 at 4:59 PM
One of the best things about being a researcher in NYC is that there is always great science happening right in your backyard 🧬🗽